The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
Cytochrome P450 CYP2D6 represents an extensively characterized polymorphic drug-metabolizing enzyme. The CYP2D6-gene is highly polymorphic and more than 70 different alleles are known currently. The activity of the enzyme markedly varies among individuals from poor to intermediate and extensive up to ultrarapid metabolism on the basis of the polymorphism of the CYP2D6 gene. Association studies provide growing evidence for the clinical importance of the CYP2D6 polymorphism investigating whether the CYP2D6 genotype distribution differs from that of the normal population either in patients with marked adverse effects or in nonresponders during treatment with CYP2D6 substrates. However, these scientifically important studies present less information for dose adjustments necessary to individualize pharmacotherapy in a given clinical case. With respect to psychopharmacological drug metabolism several antidepressants were characterized as being CYP2D6 substrates. Thus, this review summarizes dose recommendations of current antidepressants.
Thuerauf
Norbert
N
Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Univeristy of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany. norbert.thuerauf@rzmail.uni-erlangen.de
Lunkenheimer
Jens
J
D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000378:metabolism*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D006801:Humans; D006899:Mixed Function Oxygenases / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011110:Polymorphism, Genetic; D013379:Substrate Specificity
D000928:Antidepressive Agents; D004364:Pharmaceutical Preparations; D006899:Mixed Function Oxygenases; D019389:Cytochrome P-450 CYP2D6